Paper40176396
Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.
Ji D and 11 others. Thorac Cancer, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data. Papers, record 40176396. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40176396
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Neoadjuvant Therapy | Major topic |
| Humans | |
| Female | |
| Middle Aged | |
| Prognosis | |
| Axilla | |
| Adult | |
| Aged | |
| Lymph Nodes | |
| Lymphatic Metastasis | |
| Chemotherapy, Adjuvant |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2021-I2M-1-014 | CAMS Innovation Fund for Medical Sciences | PubMed | ||
| 2022-I2M-2-002 | CAMS Innovation Fund for Medical Sciences | PubMed | ||
| 2023-I2M-C&T-B-077 | CAMS Innovation Fund for Medical Sciences | PubMed | ||
| CICAMS-MOMP202203 | Major project of Medical Oncology Key Foundation of Cancer Hospital Chinese Academy of Medical Sciences | PubMed |
Source PubMed
References30
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 714108 | Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer. | N Engl J Med | 1978 | https://conductscience.org/library/papers/714108 | PubMed |
| 2 | 29368152 | A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. | Ann Surg Oncol | 2018 | https://conductscience.org/library/papers/29368152 | PubMed |
| 3 | 28075166 | The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. | Future Oncol | 2017 | https://conductscience.org/library/papers/28075166 | PubMed |
| 4 | 9215816 | Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. | J Clin Oncol | 1997 | https://conductscience.org/library/papers/9215816 | PubMed |
| 5 | 31928404 | Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. | J Clin Oncol | 2020 | https://conductscience.org/library/papers/31928404 | PubMed |
| 6 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 7 | 17545614 | Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. | Cancer Res | 2007 | https://conductscience.org/library/papers/17545614 | PubMed |
| 8 | 9704717 | Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. | J Clin Oncol | 1998 | https://conductscience.org/library/papers/9704717 | PubMed |
| 9 | 30373556 | Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. | BMC Cancer | 2018 | https://conductscience.org/library/papers/30373556 | PubMed |
| 10 | 18484198 | Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. | Breast Cancer Res Treat | 2009 | https://conductscience.org/library/papers/18484198 | PubMed |
| 11 | 25501357 | The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. | PLoS One | 2014 | https://conductscience.org/library/papers/25501357 | PubMed |
| 12 | 34171619 | Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer - A retrospective cohort study. | Breast | 2021 | https://conductscience.org/library/papers/34171619 | PubMed |
| 13 | 30814109 | Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30814109 | PubMed |
| 14 | 32046998 | Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. | Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32046998 | PubMed |
| 15 | 28564564 | Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28564564 | PubMed |
| 16 | 33232761 | Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. | Ann Oncol | 2021 | https://conductscience.org/library/papers/33232761 | PubMed |
| 17 | 25781576 | Ki67--no evidence for its use in node-positive breast cancer. | Nat Rev Clin Oncol | 2015 | https://conductscience.org/library/papers/25781576 | PubMed |
| 18 | 23828499 | Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/23828499 | PubMed |
| 19 | 25332249 | Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. | J Clin Oncol | 2014 | https://conductscience.org/library/papers/25332249 | PubMed |
| 20 | 29758503 | MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. | Breast | 2018 | https://conductscience.org/library/papers/29758503 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40176396
GET https://conductscience.org/api/papers/v1/40176396/references?page=2